Sustained release of carmustine (BCNU) for treatment of experimental intraocular malignancy

L. H.S. Liu, M. F. Refojo, C. Ni, N. Ueno, Daniel Albert

Research output: Contribution to journalArticle

Abstract

Sustained release of carmustine (1,3-bis[2-chloroethyl]-1-nitrosourea, or BCNU) via an episcleral implanted silicone device was used to treat Greene hamster melanoma implanted in the anterior chamber of rabbit eyes. Group 1 animals received carmustine intravenously; group 2 received the drug by local sustained release via an episcleral implanted silicone device; group 3 received the drug by both local sustained release and intravenous injection (a total dosage more than twice that in group 1); and group 4 was not treated. The effectiveness of the various administration routes was compared by clinical observation of tumour size and systemic and local toxic reactions, and by histopathological examination. Carmustine delayed the growth of Greene melanoma in all 3 treated groups, but was most effective when a lower dose of the drug administered intravenously was combined with an additional higher dose administered by local sustained release. Local side effects included corneal clouding and conjunctival oedema and congestion at the early stage of local drug delivery via the episcleral implanted device.

Original languageEnglish (US)
Pages (from-to)479-484
Number of pages6
JournalUnknown Journal
Volume67
Issue number7
DOIs
StatePublished - Jan 1 1983
Externally publishedYes

Fingerprint

Carmustine
Silicones
Neoplasms
Pharmaceutical Preparations
Equipment and Supplies
Melanoma
Therapeutics
Poisons
Anterior Chamber
Intravenous Injections
Cricetinae
Edema
Observation
Rabbits
Growth

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Cite this

Sustained release of carmustine (BCNU) for treatment of experimental intraocular malignancy. / Liu, L. H.S.; Refojo, M. F.; Ni, C.; Ueno, N.; Albert, Daniel.

In: Unknown Journal, Vol. 67, No. 7, 01.01.1983, p. 479-484.

Research output: Contribution to journalArticle

Liu, L. H.S. ; Refojo, M. F. ; Ni, C. ; Ueno, N. ; Albert, Daniel. / Sustained release of carmustine (BCNU) for treatment of experimental intraocular malignancy. In: Unknown Journal. 1983 ; Vol. 67, No. 7. pp. 479-484.
@article{4bdb26c7edea4e8abea02c42eace3e74,
title = "Sustained release of carmustine (BCNU) for treatment of experimental intraocular malignancy",
abstract = "Sustained release of carmustine (1,3-bis[2-chloroethyl]-1-nitrosourea, or BCNU) via an episcleral implanted silicone device was used to treat Greene hamster melanoma implanted in the anterior chamber of rabbit eyes. Group 1 animals received carmustine intravenously; group 2 received the drug by local sustained release via an episcleral implanted silicone device; group 3 received the drug by both local sustained release and intravenous injection (a total dosage more than twice that in group 1); and group 4 was not treated. The effectiveness of the various administration routes was compared by clinical observation of tumour size and systemic and local toxic reactions, and by histopathological examination. Carmustine delayed the growth of Greene melanoma in all 3 treated groups, but was most effective when a lower dose of the drug administered intravenously was combined with an additional higher dose administered by local sustained release. Local side effects included corneal clouding and conjunctival oedema and congestion at the early stage of local drug delivery via the episcleral implanted device.",
author = "Liu, {L. H.S.} and Refojo, {M. F.} and C. Ni and N. Ueno and Daniel Albert",
year = "1983",
month = "1",
day = "1",
doi = "10.1136/bjo.67.7.479",
language = "English (US)",
volume = "67",
pages = "479--484",
journal = "Indian Journal of Rheumatology",
issn = "0973-3698",
publisher = "Elsevier (Singapore) Pte Ltd",
number = "7",

}

TY - JOUR

T1 - Sustained release of carmustine (BCNU) for treatment of experimental intraocular malignancy

AU - Liu, L. H.S.

AU - Refojo, M. F.

AU - Ni, C.

AU - Ueno, N.

AU - Albert, Daniel

PY - 1983/1/1

Y1 - 1983/1/1

N2 - Sustained release of carmustine (1,3-bis[2-chloroethyl]-1-nitrosourea, or BCNU) via an episcleral implanted silicone device was used to treat Greene hamster melanoma implanted in the anterior chamber of rabbit eyes. Group 1 animals received carmustine intravenously; group 2 received the drug by local sustained release via an episcleral implanted silicone device; group 3 received the drug by both local sustained release and intravenous injection (a total dosage more than twice that in group 1); and group 4 was not treated. The effectiveness of the various administration routes was compared by clinical observation of tumour size and systemic and local toxic reactions, and by histopathological examination. Carmustine delayed the growth of Greene melanoma in all 3 treated groups, but was most effective when a lower dose of the drug administered intravenously was combined with an additional higher dose administered by local sustained release. Local side effects included corneal clouding and conjunctival oedema and congestion at the early stage of local drug delivery via the episcleral implanted device.

AB - Sustained release of carmustine (1,3-bis[2-chloroethyl]-1-nitrosourea, or BCNU) via an episcleral implanted silicone device was used to treat Greene hamster melanoma implanted in the anterior chamber of rabbit eyes. Group 1 animals received carmustine intravenously; group 2 received the drug by local sustained release via an episcleral implanted silicone device; group 3 received the drug by both local sustained release and intravenous injection (a total dosage more than twice that in group 1); and group 4 was not treated. The effectiveness of the various administration routes was compared by clinical observation of tumour size and systemic and local toxic reactions, and by histopathological examination. Carmustine delayed the growth of Greene melanoma in all 3 treated groups, but was most effective when a lower dose of the drug administered intravenously was combined with an additional higher dose administered by local sustained release. Local side effects included corneal clouding and conjunctival oedema and congestion at the early stage of local drug delivery via the episcleral implanted device.

UR - http://www.scopus.com/inward/record.url?scp=0020549638&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020549638&partnerID=8YFLogxK

U2 - 10.1136/bjo.67.7.479

DO - 10.1136/bjo.67.7.479

M3 - Article

C2 - 6860615

AN - SCOPUS:0020549638

VL - 67

SP - 479

EP - 484

JO - Indian Journal of Rheumatology

JF - Indian Journal of Rheumatology

SN - 0973-3698

IS - 7

ER -